Switzerland approves infant malaria drug, Coartem Baby

newindianexpress.com

Switzerland has approved Coartem Baby, the world's first malaria treatment specifically designed for infants, a significant step in combating the disease. The drug, developed by Novartis, is a reformulation of the existing Coartem therapy and is approved for newborns and infants weighing between 2 and 5 kilograms. It was developed in collaboration with Medicines for Malaria Venture and showed positive results in clinical trials. Malaria disproportionately affects young children in Africa, making this approval a crucial advancement in global health efforts to reduce malaria transmission and mortality.


With a significance score of 6, this news ranks in the top 0.2% of today's 26426 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers: